Navigation Links
Cetero Research Seminars Provide Insights on Designing Accelerated Proof-of-Concept Studies
Date:4/20/2011

CARY, N.C., April 20, 2011 /PRNewswire/ -- Cetero Research, the leading early-phase contract research organization (CRO), will present a scientific seminar series for pharmaceutical and biotechnology researchers entitled "Practical Insights for Designing and Conducting an Accelerated Proof-of-Concept Program." The seminars, the continuation of a series that occurred in the fall of 2010, will share best practices on how to run successful studies by developing robust protocols, ensuring safety and recruiting effectively for innovative accelerated proof-of-concept study designs. The six-city tour will kick off on April 28 in Bridgewater, NJ.

"Pharmaceutical and biotechnology companies are very interested in the efficiencies that this approach can bring to their early-phase clinical studies. However, there are a number of complexities involved in developing these studies to successfully combine multiple protocols into a single study," said Troy W. McCall, Ph.D., Chief Executive Officer of Cetero Research. "Cetero leadership and independent industry experts will share case studies and best practices."

The scientific sessions will cover three aspects of Accelerated Proof-of-Concept (AcPOC) study design and conduct: protocol development, safety in first-in-human trials and patient recruitment strategies. The seminars will offer real-world advice on creating studies that strike a balance between the strict schedule to which accelerated studies must adhere and the built-in flexibility that these trials require for troubleshooting, efficiency and regulatory approval.

"With the accelerated approach, the protocol must be a living document that can be adjusted as you move through each component of the study. There needs to be flexibility in adapting to feedback from regulators and reactions from participants," said Alan Copa, PharmD, President, Clinical Operations - Fargo for Cetero Research. "With the increasing demand for this type of study, it is important to discuss the best practices that will ensure the most efficient, robust study design possible."

Each seminar will last two hours and include three presentations as well as a question and answer session. The series schedule is as follows:

  • Thursday, April 28 — Bridgewater, NJ
  • Wednesday, May 4 — Northbrook, IL
  • Tuesday, May 10 — King of Prussia, PA
  • Wednesday, May 11 — Cambridge, MA
  • Tuesday, May 17 — La Jolla, CA
  • Wednesday, May 18 — San Jose, CA

The Cetero sessions are complimentary, but pre-registration is required. For more information about the series or to register for a session, please email rsvp@cetero.com, visit http://www.cetero.com/acpocseminar/spring or call 877-7CETERO.

About Cetero Research

Cetero Research, the leading early-phase contract research organization (CRO), has conducted more than 20,000 clinical pharmacology studies, more than any other CRO. With facilities across North America, Cetero offers flexible, high-quality clinical development services in a range of therapeutic areas, including asthma and allergy, dermatology and diabetes, as well as bioanalytical services to support clinical, preclinical drug and biomarker analysis for small and large molecules. It uses innovative approaches, such as the Accelerated-Proof-of-Concept study design, to provide key decision-making data earlier in the development process. A pioneer in the pharmaceutical and biotechnology space, Cetero prioritizes ensuring the safety of its patient and normal healthy study participants, reporting high-quality, reliable data and providing on-time results. For more information, visit www.cetero.com or call 877.7CETERO.


'/>"/>
SOURCE Cetero Research
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study
2. Cetero Research Names Dr. Roger Hayes President of Bioanalytical Operations
3. Cetero Research Launches Seminar Series on Accelerated Proof-of-Concept in Drug Development
4. Cetero Research Leads Industry in Human Allergy Models
5. Premier Research Re-brands its Medical Device Business Unit to D-TARGET
6. Australian Center Readies Brain Research Program for Addition of Elekta MEG System
7. Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research
8. Thorne Research and Integrative Health Resources Establish Joint Venture to Provide Full Range of Services in Practice Development, Patient and Clinician Education, and Access to Nutritional Supplements in Integrative Medicine
9. New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease
10. Kanzius Cancer Research Foundation Earns $1 for Each New Facebook Fan
11. Phase I Research of Extended-Release Topiramate Shows Less Fluctuation in Plasma Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016 Research and Markets has ... report to their offering. ... The report forecasts the global optical transceiver market ... The report covers the present scenario and the ... calculate the market size, the report considers the revenue generated from ...
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company ... severe, rare diseases, today announced that senior management will participate in ... Conference at the InterContinental Barclay Hotel in New York ... ET. About aTyr Pharma ... aTyr Pharma is engaged in the ...
(Date:12/9/2016)... Bermuda , Dec. 9, 2016  Axovant ... leading clinical-stage biopharmaceutical company focused on the treatment ... the data from a Phase 2b trial evaluating ... care donepezil, compared with donepezil plus placebo in ... that the addition of intepirdine to treatment was ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... , ... "I have gout, and I wanted to treat it naturally," said ... to relieve gout and pain caused by varicose veins. I drank it every morning ... relieved what VA doctors called the worst sinusitis case they'd seen and relieved gas, ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical Center ... NY, on December 3rd, to benefit Holy Name Medical Center's programs and services. ... raised over $1 million - the largest event in the Center's history, both ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric ... patient safety. Only a few hospitals and facilities have earned this distinction. This ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the ... and Eric Hoessel to vice president of sales. , Litsinger joined Mirixa ...
(Date:12/8/2016)... ... 08, 2016 , ... SunView Software aims to redefine IT ... both engaging and easy to use. Coming off the heels of a successful ... its plans to roll out new AI-powered self-service enhancements to help organizations implement ...
Breaking Medicine News(10 mins):